OMERS ADMINISTRATION Corp Purchases New Position in Sarepta Therapeutics, Inc. $SRPT

OMERS ADMINISTRATION Corp purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 48,054 shares of the biotechnology company’s stock, valued at approximately $864,000.

Several other hedge funds have also bought and sold shares of the stock. iSAM Funds UK Ltd acquired a new stake in Sarepta Therapeutics during the third quarter valued at $25,000. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $25,000. Meeder Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $27,000. Ancora Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Allworth Financial LP grew its position in shares of Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research note on Wednesday, August 19th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, July 9th. Piper Sandler dropped their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, July 9th. Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $21.59 on Friday. The company has a market cap of $2.28 billion, a PE ratio of -7.44, a price-to-earnings-growth ratio of 0.29 and a beta of 0.23. The stock’s 50 day simple moving average is $17.66 and its 200-day simple moving average is $18.30. Sarepta Therapeutics, Inc. has a 1-year low of $14.68 and a 1-year high of $25.32. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same period in the previous year, the business earned $2.02 earnings per share. The firm’s revenue for the quarter was down 34.3% on a year-over-year basis. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.